The proteasome: A worthwhile target for the treatment of solid tumours?

European Journal of Cancer

Volumn 43, Issue 7, 2007, Pages 1125-1133

  Milano, Amalia ^a   Iaffaioli, Rosario Vincenzo ^a   Caponigro, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Apoptosis; Bortezomib; Clinical studies; Cyclin dependent kinase; Cyclins; Multiple myeloma; NF B; Preclinical studies; Proteasome; Solid tumours

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; PACLITAXEL; PROTEASOME; TAXANE DERIVATIVE; TIPIFARNIB;

ABDOMINAL PAIN; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; CELL CYCLE REGULATION; CHEMOSENSITIZATION; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG PROTEIN BINDING; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN STABILITY; RADIOSENSITIZATION; SENSORY NEUROPATHY; SOLID TUMOR; SYNCOPE; THROMBOCYTOPENIA; TUMOR XENOGRAFT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; UBIQUITIN;

EID: 34247125164     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.038     Document Type: Article

References (63)

1. Glickman M.H., and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82 (2002) 373-428
2. Adams J. The proteasome structure, function, and role in the cell. Cancer Treat Rev 29 (2003) 3-9
3. Ciechanover A., and Schwartz A.L. The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95 (1998) 2727-2730
4. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
5. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127 (2004) 165-172
6. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 (2005) 2487-2498
7. Nagata Y., Anan T., Yoshida T., et al. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 association. Oncogene 18 (1999) 6037-6049
8. An W.G., Hwang S.G., Trepel J.B., and Blagosklonny M.V. Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14 (2000) 1276-1283
9. Alessandrini A., Chiaur D.S., and Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11 (1997) 342-345
10. Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5 (2000) 939-948
11. Palombella V.J., Conner E.M., Fuseler J.W., et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95 (1998) 15671-15676
12. Delcros J.G., Floc'h M.B., Prigent C., and Arlot-Bonnemains Y. Proteasome inhibitors as therapeutic agents: current and future strategies. Curr Med Chem 10 (2003) 479-503
13. Pickart C.M. Back to the future with ubiquitin. Cell 116 (2004) 181-190
14. Ludwig H., Khayat D., Giaccone G., and Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 9 (2005) 1794-1807
15. Almond J.B., and Cohen G.M. The proteasome: structure, function, and role in the cell. Leukemia 16 (2002) 433-443
16. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 (2002) 301-310
17. Olivier S., Robe P., and Bours V. Can NF-κB be a target for novel and efficient anti-cancer agents?. Biochem Pharmacol 72 (2006) 1054-1068
18. Read M.A., Neish A.S., Luscinskas F.W., Palombella V.J., Maniatis T., and Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2 (1995) 493-506
19. Oikawa T., Sasaki T., Nakamura M., et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 246 (1998) 243-248
20. Ling Y.H., Liebes L., Ng B., et al. PS-341, a novel proteasome inhibitor, induces bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1 (2002) 841-849
21. Ling Y.H., Lieves L., Jiang J.D., et al. Mechanism of proteasome inhibitor PS-341 induced G2-M phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9 (2003) 1145-1154
22. Ling Y.H., Liebes L., Zou Y., and Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278 (2003) 33714-33723
23. Williams S., Pettaway C., Song R., Papandreou C., Logothetis C., and McConkey D.J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2 (2003) 835-843
24. Shah S.A., Potter M.W., McDade T.P., et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82 (2001) 110-122
25. Ma M.H., Yang H.H., Parker K., et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9 (2003) 1136-1144
26. Russo S.M., Tepper J.E., Baldwin A.S., et al. Enhancement of radiosensitivity by proteasome inhibition; implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
27. Wang C.Y., Mayo M.W., and Baldwin Jr. A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF kappa B. Science 274 (1996) 784-787
28. Cusack J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61 (2001) 3535-3540
29. Bold R.J., Virudachalam S., and McConkey D.J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100 (2001) 11-17
30. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101 (2003) 2377-2380
31. Loo T.W., and Clarke D.M. The human multidrug resistance P glycoprotein is inactive when its maturation is inhibited potential for a role in cancer chemotherapy. FASEB J 13 (1999) 1724-1732
32. Hideshima T., Mitsiades C., Akiyama M., et al. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 101 (2003) 1530-1534
33. Orlowski R.Z. The ubiquitin proteasome pathway from bench to bedside. Hematology Am Soc Hematol Educ Program (2005) 220-225
34. Cusack J, Wang F, Sloss C, Lu R, Xia L. EGFR activation and ERK signalling is triggered by proteasome inhibitors: implication for combining proteasome inhibitors with EGFR inhibitors. Eur J Cancer 2006;4:abs 179.
35. Cascone T, Morgillo F, Laus G, Pepe S, Ciardiello F. Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines. Eur J Cancer 2006;4:abs 397.
36. Klass CM, Chen ZG, Zhang X, et al. Antitumor effects of combined bortezomib and tipifarnib in head and neck cell carcinoma (HNSCC) cells.Proc Am Soc Clin Oncol 2006;24:abs 5581.
37. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 11 (2004) 2108-2121
38. Dy G.K., Thomas J.P., Wilding G., et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (Bortezomib, Velcade), in patients with advanced cancer. Clin Cancer Res 11 (2005) 3410-3416
39. Hegewisch-Becker S, Sterneck M, Schubert U, et al. Phase I/II trial of bortezomib in patients with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2004;22:abs 4089.
40. Bardag-Gorce F., Li J., French B.A., and French S.W. Ethanol withdrawal induced CYP2E1 degradation in vivo, blocked by proteasomal inhibitor PS-341. Free Radic Biol Med 32 (2002) 17-21
41. Korsmeyer K.K., Davoll S., Figueiredo-Pereira M.E., and Correia M.A. Proteolytic degradation of heme-modified hepatic cytochromes P450: A role for phosphorylation, ubiquitination, and the 26S proteasome?. Arch Biochem Biophys 365 (1999) 31-44
42. Messersmith W.A., Baker S.D., Lassiter L., et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 12 (2006) 1270-1275
43. Shapiro CL, Ramaswamy B, Young D, et al. Phase I trial of bortezomib (Velcade) in combination with paclitaxel in advanced solid tumor patients (pts). Proc Am Soc Clin Oncol 2005;23:abs 3104.
44. Ryan D.P., O'Neil B.H., Supko J.G., et al. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107 (2006) 2688-2697
45. Bergman A.M., Pinedo H.M., Jongsma A.P., et al. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycytidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukaemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57 (1999) 397-406
46. Ryan D.P., Appleman L.J., Lynch T., et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer 107 (2006) 2482-2489
47. Denlinger C.E., Rundall B.K., Keller M.D., and Jones D.R. Proteasome inhibition sensitizes non-small-cell-lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78 (2004) 1204-1214
48. Iqbal S, Cole S, Yang D, et al. Phase I study of PS-341 (bortezomib) with 5-fluorouracil/leucovorin (5-FU/LV) in advanced solid tumors: A California Cancer Consortium study. Proc Am Soc Clin Oncol 2004;22:abs 2057.
49. Davies M, Lara PN, Lau DH, et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study. Proc Am Soc Clin Oncol 2004;22:abs 7106.
50. Agajanian C., Dizon D.S., Sabbatini P., Raizer J.J., Dupont J., and Spriggs D.R. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23 (2004) 5943-5949
51. Markovic S., Geyer S.M., Dawkins F., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589
52. Maki R.G., Kraft A.S., Scheu K., et al. A Multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103 (2005) 1431-1438
53. Fenteany G., and Schreiber S.L. Specific inhibition of the chymotrypsin like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem Biol 3 (1996) 905-912
54. Shah M.H., Young D., Kindler H.L., et al. Phase II Study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 10 (2004) 6111-6118
55. Mackay H, Major P, Townsley C, et al. A phase II trial of the proteasome inhibitor PS-341 in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004;22:abs 3109.
56. Kondagunta G.V., Druker B., Schwartz L., et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22 (2004) 3720-3725
57. Davis N.B., Taber D.A., Ansari R.H., et al. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II Consortium Study. J Clin Oncol 22 (2004) 111-119
58. Brown J, Von Roenn J, O'Regan R, et al. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004;22:abs 546.
59. Yang C.H., Gonzalez-Angulo A.M., Reuben J.M., et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 17 (2006) 813-817
60. Dragovich T, Lenz HJ, Rocha Lima CMS, et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from phase (ph) 2b study. Proc Am Soc Clin Oncol 2004;22:abs 3591.
61. Alberts S.R., Foster N.R., Morton R.F., et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 16 (2005) 1654-1661
62. Fanucchi M.P., Fossella F.V., Belt R., et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5025-5033
63. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132